ArticleNeurobiology of aging2022
Biological correlates of elevated soluble TREM2 in cerebrospinal fluid.
Open access · hybridAbstract read
In one paragraph
Article in Neurobiology of aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Neuroinflammatory markers sTREM2 and YKL-40 in association with Alzheimer's disease pathology: a systematic review and meta-analysis.Molecular psychiatry · 2026Pooled it
- Association of soluble TREM2 with Alzheimer's disease and mild cognitive impairment: a systematic review and meta-analysis.Frontiers in aging neuroscience · 2024Pooled it
- Inhibition of p38α MAPK increases short-term astrocyte reactivity: the exploratory VIP trial in early Alzheimer's disease.Journal of neuroinflammation · 2025Trial
- Assessing the Clinical Relevance of Blood Soluble Triggering Receptor Expressed on Myeloid Cells 2 in Neurological Diseases.The European journal of neuroscience · 2026Observational
- Soluble TREM2 Mediates Blood Brain Barrier Permeability through Astrocyte Reactivity.Research square · 2026Article
- Evaluation of Soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in Cerebrospinal Fluid, Serum, and Plasma Using the Fully Automated Lumipulse Platform.Journal of clinical laboratory analysis · 2026Article
- Synthetic cleavage-resistant TREM2 boosts macrophage efferocytosis to treat inflammatory diseases.Cell reports. Medicine · 2026Article
- Role of TREM2 in neuroinflammation regulation: mechanisms, disease associations, and therapeutic translation advances.Journal of translational medicine · 2025Review
- Roles of TREM2 in Alzheimer's disease.Translational neurodegeneration · 2025Review
- Vascular endothelial growth factor receptor-1 (FLT1) interactions with amyloid-beta in Alzheimer's disease: A putative biomarker of amyloid-induced vascular damage.Neurobiology of aging · 2025Article
- Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches?Journal of neuroinflammation · 2024Review
- Neuroimaging biomarkers and CSF sTREM2 levels in Alzheimer's disease: a longitudinal study.Scientific reports · 2024Article
- Variants in the MS4A cluster interact with soluble TREM2 expression on biomarkers of neuropathology.Molecular neurodegeneration · 2024Article
- Increased CX3CL1 in cerebrospinal fluid and ictal serum t-tau elevations in migraine: results from a cross-sectional exploratory case-control study.The journal of headache and pain · 2024Article
- Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer's disease.Molecular neurodegeneration · 2024Article
- Blood-Brain Barrier Breakdown in Alzheimer's Disease: Mechanisms and Targeted Strategies.International journal of molecular sciences · 2023Review
- Soluble TREM2 in body fluid in Alzheimer's disease and Parkinson's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Article
- Soluble TREM2 Concentrations in the Cerebrospinal Fluid Correlate with the Severity of Neurofibrillary Degeneration, Cognitive Impairment, and Inflammasome Activation in Alzheimer's Disease.Neurology international · 2023Article
- A Perspective: Challenges in Dementia Research.Medicina (Kaunas, Lithuania) · 2022Article
- TREM2 in Alzheimer's disease: A global bibliometric analysis of research evolution and therapeutic implications.Journal of Alzheimer's disease reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 3 countries.
Rebecca L WinfreeVanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN, USA; Pharmacology Department, Vanderbilt University Medical Center, Nashville, TN, USA.
Logan DumitrescuVanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA; Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK; UK Dementia Research Institute at UCL, London, UK.
Katherine A GiffordVanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.
Kimberly R PechmanVanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.
Angela L JeffersonVanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.
Timothy J HohmanVanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN, USA; Pharmacology Department, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA; Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: timothy.j.hohman@vumc.org.
Alzheimer's Disease Neuroimaging Initiative
Vanderbilt University Medical Center · USSahlgrenska University Hospital · SE
Funding
Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI Duygu Tosun-Turgut · 2016 to 2026
$226.7MAlzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0MVanderbilt Memory & Aging ProjectR01AG034962 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JEFFERSON, ANGELA L. · 2011 to 2025
$24.1MNeuroprotective Effects of Vascular Endothelial Growth Factor in Alzheimer's DiseaseR01AG061518 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Timothy J Hohman · 2019 to 2026
$5.9MVanderbilt Alzheimer's Disease Research CenterP20AG068082 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI NEWHOUSE, PAUL A. · 2020 to 2023
$5.6MGenetic Drivers of Resilience to Alzheimer's DiseaseR01AG059716 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HOHMAN, TIMOTHY J · 2018 to 2022
$4.4MVanderbilt Interdisciplinary Training Program in Alzheimer's DiseaseT32AG058524 · NIA · VANDERBILT UNIVERSITY · PI ANGELA L. JEFFERSON · 2018 to 2026
$3.5MThe effects of iron on oxidative stress and Alzheimer's biomarkers in amyloid-positive and negative elderly normalR01AG068398 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHIANG, GLORIA CHIA-YI · 2020 to 2024
$2.8MRisk factors and prevention targets for abnormal cognitive agingK24AG046373 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JEFFERSON, ANGELA L. · 2014 to 2023
$1.7MGenetic Resilience to the Clinical Manifestation of DementiaK01AG049164 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HOHMAN, TIMOTHY J · 2016 to 2020
$595kSex-Specific Genetic Drivers of Alzheimer's Disease NeuropathologyR21AG059941 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HOHMAN, TIMOTHY J · 2018 to 2019
$435kCIHRNIA NIH HHS K01 AG049164NIA NIH HHS K24 AG046373NIA NIH HHS P20 AG068082NIA NIH HHS R01 AG034962NIA NIH HHS R01 AG059716NIA NIH HHS R01 AG061518NIA NIH HHS R01 AG068398NIA NIH HHS R21 AG059941NIA NIH HHS T32 AG058524NIA NIH HHS U01 AG024904NIA NIH HHS U19 AG024904
Abstract
Cerebrospinal fluid (CSF) soluble triggering receptor expressed on myeloid cells-2 (sTREM2) is an emerging biomarker of neuroinflammation in Alzheimer's disease (AD). Yet, sTREM2 expression has not been systematically evaluated in relation to concomitant drivers of neuroinflammation. While associations between sTREM2 and tau in CSF are established, we sought to determine additional biological correlates of CSF sTREM2 during the prodromal stages of AD by evaluating CSF Aβ species (Aβ
Indexed as
Alzheimer DiseaseAmyloid beta-PeptidesBiomarkersHumansMembrane GlycoproteinsReceptors, ImmunologicSerum Albumintau ProteinsAmyloid beta-PeptidesBiomarkersMembrane GlycoproteinsReceptors, ImmunologicSerum Albumintau ProteinsTREM2 protein, humanAlzheimer's diseaseBlood-brain barrierCerebrovascular injuryCSF biomarkersMicrogliasTREM2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.